

ORIGINAL PAPER

THE UTILITY OF GLOMERULAR C4D IMMUNOSTAINING IN RENAL BIOPSIES IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY. A CLINICOPATHOLOGICAL STUDYMALGORZATA WĄGROWSKA-DANILEWICZ¹, MARIAN DANILEWICZ²¹Department of Nephropathology, Medical University of Lodz, Poland²Department of Pathomorphology, Medical University of Lodz, Poland

The course of IgA nephropathy (IgAN) is highly variable and ranges from a totally benign condition to end-stage renal disease in approximately one third of cases. The identification of new prognostic markers could provide insights into the pathogenesis of IgAN and unveil new therapeutic avenues. Glomerular deposition of C4d is a marker of activation of the lectin pathway of complement. It is thought that activation of the lectin pathway in IgAN is associated with more severe renal damage, and more severe histological findings.

In view of the above, the aim of the present study was to compare the clinical presentation, laboratory data, and histological lesions in the renal biopsy in IgAN patients with positive and negative staining for mesangial C4d depositions.

Our study revealed that hypertension, severe proteinuria, a high level of serum creatinine, low eGFR at the time of presentation, as well as tubular atrophy/interstitial fibrosis > 50%, and endocapillary proliferation were significantly more frequent in the C4d (+) group than in the C4d (-) group. Based on our research, we can assume that mesangial immunoexpression of C4d seems to be a useful prognostic factor in IgAN.

Key words: IgA nephropathy, C4d staining, outcome of IgA nephropathy.

Introduction

IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide [1], and it accounts for about 20% of biopsies performed for glomerular disease in Poland [2]. This glomerulopathy presently can only be diagnosed by immunohistological examination of a kidney biopsy [3]. Although the light-microscopic pattern of IgA nephropathy may vary widely, it is usually characterised by mesangioproliferative changes in glomeruli with deposition of IgA [4]. Mesangial IgA deposition induces an inflammatory process that involves mesangial proliferation, interstitial damage, and proteinuria [5]. Activation of complement plays a key role in the

pathogenesis of IgAN [6, 7]. Complement activation runs through three pathways: classic, alternative, and mannose-binding lectin. Recent data have revealed the ability of polymeric IgA to activate the lectin pathway [5, 8, 9, 10]. The course of IgA nephropathy is highly variable and ranges from a totally benign condition [11] to end-stage renal disease in approximately one third of cases [5, 12, 13]. Some clinical and histological factors, such as arterial hypertension, proteinuria, renal function, and Oxford classification score, determine the final outcome of patients with IgAN [14]. The identification of new prognostic markers could provide insights into pathogenesis of IgAN and unveil new therapeutic avenues [15]. Glomerular deposition of C4d is a marker of activation of

the lectin pathway of complement [5]. It is thought that activation of the lectin pathway in IgAN is associated with more severe renal damage, and more severe histological findings [5, 15, 16].

In view of the above, the aim of the present study was to compare the clinical presentation, laboratory data, and histological lesions in the renal biopsy in IgAN patients with positive and negative staining for mesangial C4d depositions.

Material and methods

Material consists of renal biopsy specimens obtained for diagnostic purposes from 43 adult patients (29 males and 14 females) with IgA nephropathy, who had undergone renal biopsy between 2010 and 2015 in the Nephropathology Centre, Medical University of Lodz. The patients' age, gender, presence of hypertension, nephrotic syndrome, urinary protein excretion level, haematuria, serum creatinine level, and glomerular filtration rate (eGFR) were noted at the time of the renal biopsy. The renal biopsy specimens were routinely processed by light microscopy and immunofluorescence (IF). Criteria applied to the biopsy specimens were as follows: minimal number of 10 non-sclerosed glomeruli for light microscopy, and a minimal number of five non-sclerosed glomeruli for immunofluorescence study. The samples were embedded in paraffin and sectioned at 2 μ m, followed by haematoxylin and eosin (HE), Masson's trichrome, periodic acid-Schiff, methenamine-silver, and Congo red staining. For IF the samples were sectioned in frozen conditions, followed by a direct staining for IgG (DAKO, polyclonal rabbit anti-human IgG/FITC antibody, dilution 1 : 10), IgA (DAKO, polyclonal rabbit anti-human IgA/FITC antibody, dilution 1 : 10), IgM (DAKO, polyclonal rabbit anti-human IgM/FITC antibody, dilution 1 : 10), C3 (DAKO polyclonal rabbit anti-human C3c Complement/

FITC antibody, dilution 1 : 20), C1q (DAKO, rabbit anti-human C1q Complement/FITC antibody, dilution 1 : 20), κ light chain (DAKO, polyclonal rabbit anti-human κ light chains/FITC antibody, dilution 1 : 10), and λ light chain (DAKO, polyclonal rabbit-anti human λ light chains/FITC antibody, dilution 1 : 10). For C4d indirect immunofluorescence method was performed: murine monoclonal anti-human C4d antibody, Quidel, diluted 1 : 50, followed by DAKO polyclonal rabbit anti-mouse immunoglobulin/FITC antibody diluted 1 : 10. All sections were mounted in aqueous medium and examined under a dark field ultraviolet fluorescence microscope (Olympus BX41). Negative controls were carried out by incubation slides with PBS in the absence of the primary antibody, and always yielded negative results.

In immunofluorescence findings the localisation of immune deposits, the intensity of immunoglobulin, components of complement staining, κ and λ light chain staining, and the class of immunoglobulin in deposits were evaluated. A semiquantitative assessment of the intensity of staining was given as: lack of staining (0), mild (+1), moderate (+2), and strong (+3).

Histological lesions were classified using Oxford pathologic classification criteria [14]. In the light microscopy the presence of mesangial proliferation – M (Fig. 1), endocapillary proliferation – E (Fig. 2), and segmental glomerular sclerosis – S (Fig. 3) and the severity of tubular atrophy/interstitial fibrosis – T (Fig. 4) were noted. On the basis of positive or negative mesangial C4d staining the studied material was classified into IgAN C4d (+) group or IgAN C4d (–) group.

Statistical analysis using Statistica 8 software was performed to assess the differences in the clinical presentation, laboratory data, and histological renal damage between both IgAN groups. The differences between groups were assessed using Mann-Whitney




Fig. 1. Mesangial proliferative lesions in the renal tissue in patient with IgAN C4d (–). HE staining, magn. 200 \times




Fig. 2. Endocapillary proliferative lesions in the renal tissue in patient with IgAN C4d (+). PAS staining, magn. 200 \times




Fig. 3. Segmental glomerular sclerosis in the renal tissue in patient with IgAN C4d (+). Methenamine-silver staining, magn. 200×




Fig. 4. Interstitial fibrosis and tubular atrophy in the renal tissue in patient with IgAN C4d (+). Masson's trichrome staining, magn. 100×

U test and univariate χ^2 test. Results were considered statistically significant if $p < 0.05$.

Results

Dominant or codominant granular IgA mesangial staining was seen in all biopsies (Fig. 5). The immunostaining for IgG and IgM was negative in all studied renal tissue specimens. The granular mesangial immunostaining for κ and λ light chains was seen in all biopsies.

Of 43 patients with IgAN, 11 were classified as C4d-positive, and 32 as C4d-negative. In the C4d-positive group mesangial pattern of C4d staining was seen (Fig. 6). C1q staining was negative in all of the patients. Strong to moderate mesangial granular immunostaining for C3 was observed in all biopsies. The IgAN C4d-positive group consisted of eight males and three females (mean age 37 ± 9 years). In the IgAN C4d-negative group there were 21 males and 11 females (mean age 33 ± 11 years). Haematu-

ria was noted in all patients in both studied groups. Clinical and laboratory data in the IgAN C4d-positive and IgAN C4d-negative groups are shown in Table I. The proportion of patients with hypertension was significantly higher (72.7% vs. 37.5%, $p < 0.001$) in C4d-positive patients. At the time of presentation, C4d-positive patients had a significantly lower eGFR (63.6% vs. 21.8%, $p < 0.001$), a higher amount of proteinuria (45.4% vs. 18.7%, $p < 0.002$), and a higher serum creatinine level (63.6% vs. 25%, $p < 0.001$), compared with C4d-negative patients.

Histological findings are shown in Table II. Histological examination of renal biopsy specimens in the C4d-positive group revealed mesangial proliferation in more than 50% glomeruli (M1, according to the Oxford classification) in nine patients (81.8%) and in 27 (84.4%) C4d-negative patients ($p = 0.76$, NS). Endocapillary proliferation (E1, according to the Oxford classification) was noted in seven C4d-positive (63.6%) and in 10 C4d-negative patients (31%) ($p < 0.001$). Segmental glomerular sclerosis (S1, accord-




Fig. 5. IF. Strong granular mesangial IgA immunostaining in the renal tissue in patients with IgAN, magn. 200×




Fig. 6. IF. Mesangial immunostaining for C4d in the renal tissue in patient with IgAN C4d- positive group, magn. 200×

Table I. Clinical and laboratory data in IgAN C4d (+) and IgAN C4d (-) groups (number of patients, %)

GROUPS	HYPERTENSION (> 140/90)	PROTEINURIA (> 3G/24 H)	SERUM CREATININE (> 1.4 MG/DL)	eGFR (< 59 ML/MIN)
C4d-positive (n = 11)	8 (72.7%)	5 (45.4%)	7 (63.6%)	7 (63.6%)
C4d-negative (n = 32)	12 (37.5%)	6 (18.7%)	8 (25%)	7 (21.8%)
P value	< 0.001	< 0.002	< 0.001	< 0.001

Table II. Histologic findings in C4d-positive and C4d-negative patients (number of patients, %)

GROUPS	MESANGIAL PROLIFERATION M1	ENDOCAPILLARY PROLIFERATION E1	SEGMENTAL GLOMERULAR SCLEROSIS S1	TUBULAR ATROPHY T2
C4d-positive (n = 11)	9 (81.8%)	7 (63.6%)	8 (72.7%)	6 (54.5%)
C4d-negative (n = 32)	27 (84.4%)	10 (31%)	24 (75%)	5 (15.6%)
P value	0.76 (NS)	< 0.001	0.79 (NS)	< 0.001

Mesangial hypercellularity in more than 50% of glomeruli (M 1)

Endocapillary hypercellularity – present (E 1)

Segmental sclerosis/adhesions – present (S 1)

Tubular atrophy/interstitial fibrosis in more than 50% of renal cortex (T 2)

ing to the Oxford classification) was seen in eight C4d-positive patients (72.7%) and in 24 from the C4d-negative group (75%) ($p = 0.79$, NS). Tubular atrophy/interstitial fibrosis (T2, according to the Oxford classification) was present in six C4d-positive (54.5%) and in five C4d-negative patients (15.6%) ($p < 0.001$).

Discussion

The variability in the clinical course of IgAN justifies efforts to determine clinical and histological features that predict the development of renal failure in this glomerulopathy, and thus to guide therapy. Recently mesangial deposition of C4d is regarded as a prognostic factor in IgAN [5, 15, 16]. Roos *et al.* [5] revealed that patients with IgAN are divided into two groups on the basis of the pattern of complement activation. In the patients with negative glomerular staining for mannose-binding lectin (C4d-negative) the activation of the complement occurs via the alternative pathway. When these stainings are positive (C4d-positive), activation of complement occurs via the lectin pathway [5]. A deeper understanding of the mechanisms of complement activation may help to elucidate the pathogenesis of IgA nephropathy [8].

In our study the C4d-positive group comprised 25.6% of IgAN patients whereas for the C4d-negative group it was 74.4%. In the study by Espinosa *et al.* [16] C4d-positive patients were more numerous: 32.2% and 67.8%, respectively. In the latter study by Espinosa *et al.* [15] these percentages were 38.5% and 61.5%, respectively. Similarly to our results,

Roos *et al.* [5] found 25% of IgAN patients to be C4d-positive and 75% C4d-negative.

Analysing the clinical data, we found, similarly to others [15, 16], that the number of patients with hypertension was significantly higher in C4d-positive patients as compared to C4d-negative individuals. The urinary protein excretion in our IgAN cases was also significantly more frequent in C4d-positive participants. In an earlier work by Espinosa *et al.* [16] this difference was not significant; however, in the latter study, [15] on a larger cohort of IgAN patients, they revealed statistical significance. Of note, in the study by Sahin *et al.* this parameter also differed significantly in C4d-positive and C4d-negative groups [17]. At the time of presentation, our C4d-positive patients had a significantly lower eGFR and a higher serum creatinine level compared with C4d-negative patients. These findings are in concordance the observations of other authors [8, 15, 16]. Interestingly, in the study by Shu *et al.* all these parameters were in IgAN patients with worse prognosis, similarly to our C4d-positive group, and differed significantly as compared to the IgAN group, with better prognosis [18].

The comparison of histological findings between the C4d-positive and C4d-negative groups revealed that mesangial proliferation in >50% glomeruli (M1, according to the Oxford classification) did not differ significantly. This observation is in an agreement with earlier studies [15, 16]. It should be noted, however, that the results of Sahin *et al.* [17] showed a highly significant difference of mesangial proliferation in these groups. On the other hand, we noted significant difference as regard endocapillary proliferation

(E1, according to the Oxford classification). This proliferation was significantly greater in C4d-positive patients as compared to the C4d-negative group. In contrast, in the study by Espinosa *et al.* this difference did not reach statistical significance [15]. It is noteworthy, however, that in the study of these authors endocapillary proliferation was also more frequent in C4d-positive participants. In the present study segmental glomerular sclerosis (S1, according to the Oxford classification) did not differ significantly in the C4d-positive and C4d-negative groups. In contrast to our findings, other authors revealed significant differences in this parameter [15, 17], whereas Roos *et al.* [5] received results similar to ours. Tubular atrophy/interstitial fibrosis (T2, according to the Oxford classification) was significantly more frequent in our C4d-positive group in comparison with C4d-negative patients. This finding is in concordance with other authors [16, 17].

In summary, our study revealed that hypertension, severe proteinuria, a high level of serum creatinine, low eGFR at the time of presentation, as well as tubular atrophy/interstitial fibrosis > 50% (T2), and endocapillary proliferation (E1) were significantly more frequent in the C4d-positive group than in the C4d-negative group. Based on our research, we can assume that mesangial immunoexpression of C4d seems to be a useful prognostic factor in IgAN.

This work was supported by a grant of the Medical University of Lodz – 503/6-038-01/503-01.

The authors declare no conflict of interest.

References

- Wyatt R, Julian B. IgA nephropathy. *N Eng J Med* 2013; 368: 2402-2414.
- Perkowska-Ptasińska A, Bartczak A, Wągrowka-Danilewicz M, et al. Chronic kidney disease. *Clinical epidemiology - 2. Nephrol Dial Transplant* 2015; 30: suppl. 3.
- Sethi S, Haas M, Markowitz GS et al. Mayo Clinic/Renal Pathology Society consensus report on pathologic classification, diagnosis and reporting of GN. *J Am Soc Nephrol* 2015; 27: 1-7.
- Floege J, Moura IC, Daha MR. New insight into the pathogenesis of IgA nephropathy. *Semin Immunopathol* 2014; 36: 431-442.
- Roos A, Rastaldi MP, Calvaresi N, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. *J Am Soc Nephrol* 2006; 17: 1724-1734.
- Daha MR, van Kooten C. Role of complement in IgA nephropathy. *J Nephrol* 2016; 29: 1-4.
- Maillard N, Wyatt RJ, Julian BA, et al. Current understanding of the role of complement in IgA nephropathy. *J Am Soc Nephrol* 2015; 26: 1503-1512.
- Ohsawa I, Ishii M, Ohi H, et al. Pathological scenario with mannose-binding lectin in patients with IgA nephropathy. *J Biomed Biotechnol* 2012; 476739: 1-5.
- Liu LL, Liu N, Chen Y, et al. Glomerular mannose-binding lectin deposition is a useful prognostic predictor in immunoglobulin A nephropathy. *Clin Exp Immunol* 2013; 174: 152-160.
- Shi B, Wang L, Mou S, et al. Identification of mannose-binding lectin as a mechanism in progressive immunoglobulin A nephropathy. *Int J Clin Exp Pathol* 2015; 8: 1889-1899.
- Gutiérrez E, Zamora I, Ballarín JA, et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. *J Am Soc Nephrol* 2012; 23: 1753-1760.
- Donadio JV, Grande JP. IgA nephropathy. *N Engl J Med* 2002; 347: 738-748.
- Le W, Liang S, Hu Y, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. *Nephrol Dial Transplant* 2012; 27: 1479-1485.
- Roberts IS, Cook HT, Troyanov S, et al. The Oxford classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility. *Kidney Int* 2009; 76: 546-556.
- Espinosa M, Ortega R, Sanchez M, et al. Association of C4d deposition with clinical outcomes in IgA nephropathy. *Clin J Am Soc Nephrol* 2014; 9: 897-904.
- Espinosa M, Ortega R, Gómez-Carrasco JM, et al. Mesangial C4d deposition: a new prognostic factor in IgA nephropathy. *Nephrol Dial Transplant* 2009; 24: 886-889.
- Sahin OZ, Yavas H, Tasli F, et al. Prognostic value of glomerular C4d staining in patients with IgA nephritis. *Int J Clin Exp Pathol* 2014; 7: 3299-3304.
- Shu D, Xu F, Su Z, et al. Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case-control study. *BMC Nephrol* 2017; 18: 1-6.

Address for correspondence

Małgorzata Wągrowka-Danilewicz
 Department of Nephropatology Medical University of Lodz
 Pomorska 251
 92-216 Łódź, Poland
 tel./fax +48 42 675 76 33
 e-mail: malgorzata.wagrowska-danilewicz@umed.lodz.pl